Assessment of Low-dose ASA Discontinuation Risk Associated With Concomitant PPI Use During the First Year of ASA Therapy for Secondary Prevention
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 35,604
- 试验地点
- 1
- 主要终点
- Risk of low dose ASA discontinuation associated with continuous PPI use vs.non-use
研究概览
简要总结
This study is conducted in a cohort of low dose aspirin (ASA) users previously ascertained .The aims of the post hoc analyses are:
To estimate the one year risk of discontinuation of use of low-dose ASA associated to PPI concomitant use versus non-use, crude and adjusted by confounding.
To estimate the one year risk of discontinuation of use of low-dose ASA associated to PPI concomitant use stratified by age and sex.
To evaluate other predictors of discontinuation of low-dose ASA during the first year of ASA therapy.
详细描述
Assessment of low-dose ASA discontinuation risk associated with concomitant PPI use during the first year of ASA therapy for secondary prevention
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 50 Years 至 84 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients aged 50-84 years in 2000-
- •Patients with first prescription of low dose ASA ( see study population description).
- •Patients were required to have been enrolled with their primary care practitioner (PCP) for at least 2 years and to have a computerized prescription history of at least 1 year before the start of the study.
排除标准
- •Patients aged below age 50 and 85 years and above ( see study population description).
- •Patients with a diagnosis of cancer, alcohol abuse or alcohol-related disease.
- •Incomplete data recording in THIN.
研究组 & 干预措施
Aspirin discontinuers; Aspirin non-discontinuers
Patients on low dose ASA for secondary prevention that discontinue aspirin and those not discontinuing aspirin
干预措施: Risk of low dose aspirin discontinuation (Drug)
结局指标
主要结局
Risk of low dose ASA discontinuation associated with continuous PPI use vs.non-use
时间窗: Up to 1 year.
Risk (hazard ratios) of low dose ASA discontinuation associated with continuous PPI use vs. non-use.
Risk of low dose ASA discontinuation associated with baseline gastrointestinal risk category ( high risk versus low risk)
时间窗: Up to 1 year
Risk ( hazard ratios) of low dose ASA discontinuation associated with baseline gastrointestinal risk category( high risk versus low risk).
次要结局
未报告次要终点